These regulatory pathways directly influence antitumor activity and affects the efficacy of PD-1/PD-L1 blockade therapy by modulating the ability of immune cells to recognize and destroy tumor cells.6 Nonetheless, there is still a pressing need for a more comprehensive understanding of the regulatory factors that govern both the response and resistance against ICB therapy. The gene discussed is CD274; the disease is neoplasm.